Last 7 days
-2.7%
Last 30 days
13.8%
Last 90 days
15.7%
Trailing 12 Months
107.4%
Name | Mkt Capsorted ascending | Revenue | Price %, 1M | Returns, 1Y | P/E | P/S | Rev 1-Yr | Inc 1-Yr |
---|---|---|---|---|---|---|---|---|
LARGE-CAP | ||||||||
BGNE | 326.1B | 1.6B | -7.40% | 77.06% | -170.12 | 209.44 | 77.54% | 1.62% |
ABBV | 285.4B | 56.7B | -12.25% | -1.83% | 24.12 | 4.92 | 0.03% | -39.22% |
REGN | 87.6B | 12.4B | -6.52% | 9.77% | 20.2 | 7.2 | -25.07% | -47.28% |
VRTX | 85.9B | 9.2B | 0.73% | 24.28% | 26.35 | 9.33 | 15.86% | 32.99% |
ALNY | 23.8B | 1.0B | -8.34% | 48.04% | -22.38 | 22.97 | 22.88% | -19.27% |
SRPT | 13.7B | 975.7M | 14.79% | 105.15% | -12.27 | 14.02 | 27.41% | -212.78% |
UTHR | 10.1B | 2.0B | -6.31% | 2.88% | 13.88 | 5.1 | 12.05% | 52.86% |
MID-CAP | ||||||||
MDGL | 5.2B | 504.0K | -7.03% | 326.29% | -16.39 | 2.5K | -66.53% | -27.52% |
RARE | 3.6B | 363.3M | 21.73% | 7.26% | -5.1 | 9.93 | 3.39% | -55.81% |
BPMC | 3.5B | 204.6M | 19.27% | 2.79% | -6.08 | 17.28 | -7.52% | 10.65% |
MRTX | 2.7B | 18.9M | 7.20% | -28.12% | -3.61 | 140.65 | - | -16.17% |
SMALL-CAP | ||||||||
CYTK | 3.7B | - | 1.75% | -2.11% | -8.59 | 39.11 | 34.30% | -67.22% |
CPRX | 1.3B | 256.5M | -26.70% | 74.57% | 12.87 | 4.99 | 66.85% | 120.61% |
MGNX | 348.8M | 165.3M | -18.85% | 42.42% | -3.82 | 2.11 | 130.70% | 57.97% |
CRBP | 46.0M | 881.7K | 23.42% | 3374.52% | -0.91 | 19.11 | -77.61% | -29.84% |
Income Statement (Last 12 Months) | ||||||
---|---|---|---|---|---|---|
Description | (%) Q/Q | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 |
Revenue | 5.6% | 67,985,000 | 64,357,000 | 62,439,000 | 57,693,000 | 54,121,000 |
Gross Profit | 5.1% | 59,591,000 | 56,703,000 | 55,459,000 | 51,489,000 | 48,336,000 |
S&GA Expenses | 3.8% | 86,012,000 | 82,838,000 | 82,622,000 | 85,175,000 | 86,646,000 |
R&D Expenses | -0.4% | 52,708,000 | 52,906,000 | 51,511,000 | 50,341,000 | 49,825,000 |
EBITDA | 4.6% | -106,350,000 | -111,421,000 | -110,703,000 | - | - |
EBITDA Margin | 11.8% | -1.70 | -1.93 | -2.05 | - | - |
Earnings Before Taxes | -2.0% | -110,153,000 | -108,028,000 | -107,163,000 | -112,252,000 | -111,503,000 |
EBT Margin | 11.8% | -1.72 | -1.95 | -2.06 | - | - |
Net Income | -1.7% | -111,604,000 | -109,783,000 | -109,366,000 | -113,746,000 | -113,277,000 |
Net Income Margin | 11.2% | -1.75 | -1.97 | -2.09 | - | - |
Free Cahsflow | 1.0% | -86,320,000 | -87,225,000 | -81,977,000 | - | - |
Balance Sheet | (In Millions) | |||||
---|---|---|---|---|---|---|
Description | (%) Q/Q | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 |
Assets | -16.7% | 113 | 136 | 128 | 146 | 166 |
Current Assets | -25.5% | 96.00 | 129 | 122 | 140 | 161 |
Cash Equivalents | -34.1% | 37.00 | 55.00 | 29.00 | 81.00 | 105 |
Inventory | 26.4% | 5.00 | 4.00 | 5.00 | 5.00 | 5.00 |
Net PPE | -15.0% | 1.00 | 1.00 | 2.00 | 2.00 | 2.00 |
Liabilities | 2.0% | 230 | 225 | 192 | 187 | 183 |
Current Liabilities | 5.5% | 25.00 | 24.00 | 19.00 | 18.00 | 19.00 |
LT Debt, Non Current | 0.4% | 98.00 | 98.00 | 72.00 | 71.00 | 71.00 |
Shareholder's Equity | -30.4% | -116 | -89.36 | -17.07 | - | - |
Retained Earnings | -5.2% | -607 | -577 | -548 | -522 | -495 |
Additional Paid-In Capital | 0.6% | 491 | 488 | 485 | 481 | 479 |
Accumulated Depreciation | 8.9% | 3.00 | 3.00 | 2.00 | - | - |
Shares Outstanding | 1.3% | 23.00 | 23.00 | 23.00 | 23.00 | 23.00 |
Cashflow (Last 12 Months) | (In Thousands) | |||||
---|---|---|---|---|---|---|
Description | (%) Q/Q | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 |
Cashflow From Operations | -2.1% | -89,370 | -87,559 | -85,877 | -86,741 | -81,487 |
Share Based Compensation | -6.3% | 9,917 | 10,580 | 13,569 | 16,644 | 19,867 |
Cashflow From Investing | -691.1% | -6,266 | 1,060 | -12,923 | 33,230 | 2,641 |
Cashflow From Financing | -72.1% | 27,063 | 97,134 | 71,734 | 70,465 | 143,057 |
99.6%
98.1%
73.8%
Y-axis is the maximum loss one would have experienced if Urogen Pharma was unfortunately bought at previous high price.
-28.3%
-23.4%
FIve years rolling returns for Urogen Pharma.
Datesorted ascending | Fund Name | Type | % Chg | $ Change | $ Held | % Portfolio |
---|---|---|---|---|---|---|
2023-05-22 | AMERIPRISE FINANCIAL INC | unchanged | - | 30,504 | 748,504 | -% |
2023-05-18 | JPMORGAN CHASE & CO | added | 8,576 | 552,000 | 558,000 | -% |
2023-05-16 | JANE STREET GROUP, LLC | new | - | 784,199 | 784,199 | -% |
2023-05-16 | SUSQUEHANNA INTERNATIONAL GROUP, LLP | added | 411 | 1,497,080 | 1,842,760 | -% |
2023-05-15 | LAZARD ASSET MANAGEMENT LLC | unchanged | - | 1,000 | 28,000 | -% |
2023-05-15 | 683 Capital Management, LLC | reduced | -15.94 | -24,937 | 175,560 | 0.01% |
2023-05-15 | FIRST MANHATTAN CO. LLC. | unchanged | - | 370 | 9,240 | -% |
2023-05-15 | MILLENNIUM MANAGEMENT LLC | added | 27.96 | 819,000 | 3,278,000 | -% |
2023-05-15 | STATE STREET CORP | reduced | -46.61 | -886,495 | 1,110,850 | -% |
2023-05-15 | Annandale Capital, LLC | unchanged | - | 31,000 | 779,000 | 0.25% |
Date Filed | Name of Filer | Percent of Class | No. of Shares | Form Type | |
---|---|---|---|---|---|
Feb 13, 2023 | stonepine capital management, llc | 5.7% | 1,304,947 | SC 13G/A | |
Dec 01, 2022 | stonepine capital management, llc | 5.2% | 1,196,908 | SC 13G | |
Jul 08, 2022 | blackrock inc. | 1.5% | 340,412 | SC 13G | |
Feb 14, 2022 | wildcat capital management, llc | 2.4% | 533,139 | SC 13G/A | |
Feb 14, 2022 | credit suisse ag/ | 4.84% | 1,085,749 | SC 13G/A | |
Feb 04, 2022 | wellington management group llp | 1.06% | 238,008 | SC 13G/A | |
Feb 03, 2022 | blackrock inc. | 7.7% | 1,728,094 | SC 13G/A | |
Feb 12, 2021 | credit suisse ag/ | 07% | 1,121,071 | SC 13G | |
Feb 12, 2021 | wildcat capital management, llc | 2.41% | 533,139 | SC 13G/A | |
Feb 11, 2021 | menora mivtachim holdings ltd. | 13.37% | 2,954,699 | SC 13G/A |
Fair Value | Very Pessimistic | Pessimistic | Base Case | Optimistic | Very Optimistic |
---|---|---|---|---|---|
Very Low Inflation | - - | - - | 1.82 -84.08% | 4.00 -65.00% | 12.28 7.44% |
Current Inflation | - - | - - | 0.21 -98.16% | 3.00 -73.75% | 10.11 -11.55% |
Very High Inflation | - - | - - | 0.75 -93.44% | 1.83 -83.99% | 7.57 -33.77% |
Date Filed | Form Type | Document | |
---|---|---|---|
May 11, 2023 | 8-K | Current Report | |
May 11, 2023 | 10-Q | Quarterly Report | |
May 01, 2023 | 10-K/A | Annual Report | |
Mar 24, 2023 | 10-K | Annual Report | |
Mar 22, 2023 | 8-K | Current Report | |
Feb 28, 2023 | 4/A | Insider Trading | |
Feb 28, 2023 | 4/A | Insider Trading | |
Feb 28, 2023 | 4 | Insider Trading | |
Feb 13, 2023 | SC 13G/A | Major Ownership Report |
Datesorted ascending | Name | Buy/Sell | $ Value | Avg. Price | # Shares | Title |
---|---|---|---|---|---|---|
2023-01-31 | Schoenberg Mark | acquired | - | - | 3,833 | chief medical officer |
2023-01-31 | Barrett Elizabeth A. | acquired | - | - | 18,333 | chief executive officer |
2023-01-31 | Smith Jason Drew | sold | -16,556 | 10.12 | -1,636 | general counsel |
2023-01-31 | Schoenberg Mark | sold | -19,228 | 10.12 | -1,900 | chief medical officer |
2023-01-31 | Smith Jason Drew | acquired | - | - | 3,333 | general counsel |
2023-01-20 | Schoenberg Mark | acquired | 613,385 | 5.00 | 122,677 | chief medical officer |
2022-10-31 | Schoenberg Mark | acquired | - | - | 500 | chief medical officer |
2022-10-31 | Schoenberg Mark | sold | -3,057 | 11.85 | -258 | chief medical officer |
2022-10-21 | Nussbaum Ran | acquired | 285,114 | 5.94 | 47,999 | - |
Condensed Consolidated Statements of Operations and Comprehensive Loss - USD ($) $ in Thousands | 3 Months Ended | |
---|---|---|
Mar. 31, 2023 | Mar. 31, 2022 | |
Revenue | $ 17,192 | $ 13,564 |
Cost of revenue | 2,265 | 1,525 |
Gross profit | 14,927 | 12,039 |
Operating expenses: | ||
Research and development expenses | 12,498 | 12,696 |
Selling, general and administrative expenses | 24,474 | 21,300 |
Operating loss | (22,045) | (21,957) |
Financing on prepaid forward obligation | (5,224) | (5,826) |
Interest expense on long-term debt | (3,553) | (282) |
Interest and other income (expense), net | 630 | (2) |
Loss before income taxes | (30,192) | (28,067) |
Income tax expense | (21) | (325) |
Net Loss | (30,213) | (28,392) |
Statements of Comprehensive Loss | ||
Net loss | (30,213) | (28,392) |
Other comprehensive loss | ||
Unrealized gain (loss) on investments | 62 | (44) |
Comprehensive Loss | $ (30,151) | $ (28,436) |
Net loss per ordinary share - basic and diluted (in dollars per share) | $ (1.30) | $ (1.25) |
Weighted average number of shares outstanding used in computation of basic and diluted loss per ordinary share (in shares) | 23,279,951 | 22,631,509 |
Condensed Consolidated Balance Sheets (Current Period Unaudited) - USD ($) $ in Thousands | Mar. 31, 2023 | Dec. 31, 2022 |
---|---|---|
Current assets: | ||
Cash and cash equivalents | $ 36,540 | $ 55,408 |
Marketable securities | 28,514 | 44,556 |
Restricted cash | 814 | 813 |
Accounts receivable | 12,493 | 12,704 |
Inventories | 5,466 | 4,325 |
Prepaid expenses and other current assets | 12,146 | 11,101 |
Total current assets | 95,973 | 128,907 |
Non-current assets: | ||
Property and equipment, net | 1,103 | 1,297 |
Restricted deposit | 224 | 223 |
Right of use assets | 2,329 | 2,452 |
Marketable securities | 10,165 | 0 |
Other non-current assets | 3,160 | 2,740 |
Total Assets | 112,954 | 135,619 |
Current liabilities: | ||
Accounts payable and accrued expenses | 17,130 | 12,383 |
Employee related accrued expenses | 4,919 | 8,257 |
Other current liabilities | 3,185 | 3,276 |
Total current liabilities: | 25,234 | 23,916 |
Non-current liabilities: | ||
Prepaid forward obligation | 101,912 | 98,923 |
Long-term debt | 97,941 | 97,537 |
Long-term lease liabilities | 1,403 | 1,586 |
Uncertain tax positions liability | 3,018 | 3,018 |
Total Liabilities | 229,508 | 224,980 |
Commitments and Contingencies (Note 18) | ||
Shareholders' Deficit: | ||
Ordinary shares, NIS 0.01 par value, 100,000,000 shares authorized at March 31, 2023 and December 31, 2022; 23,440,521 and 23,129,953 shares issued and outstanding as of March 31, 2023 and December 31, 2022, respectively | 64 | 63 |
Additional paid-in capital | 490,744 | 487,787 |
Accumulated deficit | (607,317) | (577,104) |
Accumulated other comprehensive loss | (45) | (107) |
Total Shareholders' Deficit | (116,554) | (89,361) |
Total Liabilities and Shareholders' Deficit | $ 112,954 | $ 135,619 |